Skip to main content

Table 6 Clinical and laboratory data evolution over two-year follow-up

From: Impact of superimposed nephrological care to guidelines-directed management by primary care physicians of patients with stable chronic kidney disease: a randomized controlled trial

CharacteristicsPCP management onlyCombined managementP*
 T0 (N = 116)T1 (N = 99)T2 (N = 93)T0 (N = 126)T1 (N = 71)T2 (N = 85) 
Blood pressure measurement
 Office SBP (mmHg)127 (26)132 (33)125 (43)131 (23)137 (19)135 (26)0.65
 Office DBP (mmHg)72 (15)71 (18)69 (24)74 (14)78 (12)75 (14)0.31
 ABPM SBP (mmHg)132 (24)135 (27)135 (17)132 (17)133 (15)126 (43)0.20
 ABPM DBP (mmHg)74 (13)73 (11)75 (10)79 (12)78 (11)76 (10)0.20
Transthoracic ultrasound
 LVHa31/97 (32%)8/29 (28%)4/29 (14%)42/112 (38%)22/62 (35%)20/50 (40%)0.22
 EF (%)54 (14)36 (27)55 (17)55 (17)43 (29)57 (16)0.21
Laboratory data
 Creatinine (mmol/l)175 (53)203 (99)221 (143)176 (75)184 (104)212 (149)0.45
 eGFR (ml/min)34 (80)32 (15)31 (16)34 (90)35 (13)32 (14)0.65
 Hemoglobin* (g/l)112 (17)117 (18)114 (26)111 (20)128 (20)124 (30)< 0.001
 Ferritin (g/l)102 (60–188)99 (41–241)215 (88–494)176 (81–405)148 (74–267)137 (82–234)0.35
 Transferrin sat. (%)24 (19)24 (18)27 (23)21 (13)26 (10)23 (11)0.44
 Calcium (mmol/l)2.4 (0.2)2.3 (0.4)2.3 (0.4)2.4 (0.2)2.4 (0.1)2.3 (0.4)0.33
 Phosphate (mmol/l)1.1 (0.3)1.2 (0.2)1.3 (0.4)1.2 +/−0.21.2 +/− 0.21.3 +/− 0.30.57
 PTH* (pmol/l)9 (7–13)11 (8–17)11 (8–32)8 (4–14)10 (6–13)9 (5–15)0.002
 Bicarbonate (mmol/l)25 (5)24 (6)26 (6)25 (5)25 (4)25 (4)0.56
 Albumin (g/l)29 (5.4)34 (6)33 (6)35 (5)35 (5)36 (4)0.19
 24-h proteinuria (g/l)0.3 (0.2–3.8)0.5 (0.1–2.0)1.5 (0.3–5.3)0.4 (0.2–1.0)0.3 (0.1–1.2)0.4 (0.2–1.1)0.97
Medications
 RAS blockers68 (59%)36 (84%)27 (68%)92 (73%)54 (82%)49 (84%)0.82
 Diuretics*62 (53%)34 (79%)31 (78%)81 (64%)40 (61%)40 (69%)0.007
 Beta-blockers70 (56%)26 (60%)22 (55%)68 (59%)39 (59%)32 (55%)0.06
 Statin65 (56%)25 (58%)19 (48%)64 (51%)40 (61%)35 (60%)0.11
 Aspirin2 (2%)2 (5%)1 (3%)5 (4%)9 (14%)8 (14%)0.90
 Insulin36 (31%)16 (37%)13 (33%)32 (25%)20 (30%)14 (25%)0.54
 Oral antidiabetic23 (20%)10 (23%)8 (20%)23 (18%)14 (21%)9 (16%)0.28
 Erythropoietin8 (7%)8 (12%)2 (5%)11 (9%)7 (11%)6 (10%)0.36
 Iron2 (2%)3 (7%)1 (3%)7 (6%)7 (11%)6 (10%)0.77
 Vitamin D19 (16%)11 (26%)11 (28%)13 (10%)18 (27%)16 (28%)0.13
  1. *Significant p-value of the interaction between time and random group: significant p-value means a difference in the evolution of the 2 groups
  2. Continuous variables are expressed as mean (SD) or median (IQR) depending on distribution. Categorical variables are expressed as n (%)
  3. T0, T1 and T2 represent baseline and follow-up at one and two years respectively
  4. aAs some patients did not have follow-up echocardiography, results are expressed as n/n (%)